Phillip A. Sharp - Jan 23, 2025 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Role
Director
Signature
By: Brett Budzinski, Attorney-in-Fact For: Phillip A. Sharp
Stock symbol
ALNY
Transactions as of
Jan 23, 2025
Transactions value $
-$1,617,638
Form type
4
Date filed
1/24/2025, 04:10 PM
Previous filing
May 20, 2024

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALNY Stock Option (right to buy) Options Exercise $0 -11.3K -100% $0.00 0 Jan 23, 2025 Common Stock 11.3K $131.21 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 2, 2024. The 11,250 options exercised and sold by the reporting person were due to expire on June 1, 2025.
F2 Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
F3 This stock option was fully vested and exercisable as of June 1, 2016.